The chief adviser for the U.S. government’s Operation Warp Speed COVID-19 vaccine program, Moncef Slaoui, on Tuesday said efficacy data readouts are expected from Pfizer Inc and Moderna Inc between next month and December.
Speaking at a symposium conducted by the Johns Hopkins University and the University of Washington, Slaoui said data readouts from leading vaccine developers are expected to come in three waves over the next several months.
The Rise of the African Multinational Enterprise: The most authoritative book on private enterprise in Africa. Get a Copy from SPRINGER
The first wave would be coming from Pfizer and Moderna, both of which are developing mRNA-based vaccines for the coronavirus, he said.
Slaoui said efficacy data on one or two vaccines will be available within the next month or two, for which there will be enough doses to immunize 30 million people between November and December.
- Afra Grill | A place for Somali gourmet, with characteristics of Indian, Mediterranean, and Ethiopian food.
- Tani Adewumi: Meet the 10-year-old Nigerian refugee who became a national chess master
- US announces priority appointments for Nigerians applying for student visa
- Afriex raises $1.2M for African expansion
- North Alabama announce signing of Ugandan forward Nkurunungi and goalkeeper Musoke
Commenting on AstraZeneca’s vaccine program, Slaoui said while the company’s U.S. study remains on hold, data readouts on the vaccine’s effectiveness may be expected somewhere in late October or November from ongoing studies in the UK, Brazil and South Africa.
“At that time, we will have very few doses to be able to, if the decision was to approve the vaccine, immunize,” he said, adding that efforts are in place to scale up manufacturing and stockpiling of the vaccine.
Reporting by Manojna Maddipatla in Bengaluru; Editing by Andrea Ricci
Read from source Reuters